Novartis wins CHMP nod for drug combo against some lung cancers

ZURICH (Reuters) - Swiss drugmaker Novartis's drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lung cancer after a key committee on Friday published a recommendation to expand the combination's indications.